NCT03243760 - Dose Escalating Study of CCI15106 Inhalation Capsules in Healthy Subjects and Moderate Chronic Obstructive Pulmonary Disease (COPD) Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 10, 2016

Primary Completion Date

July 20, 2016

Study Completion Date

August 20, 2016

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

CCI15106 7.5 mg capsule

Orange capsule containing a white to off-white powder, 21.4 mg of CCI15106: Trehalose:Trileucine 35/55/10 weight by weight (w/w)

DRUG

Placebo

Orange capsule containing a white to off-white powder, 21.4 mg of Trehalose:Trileucine 85/15 w/w

DRUG

Placebo-2

Orange capsule containing a white to off-white powder, 21.4 mg of lactose. Placebo-2 to be used if unexpected safety signals are observed with the use of matching placebo.

Trial Locations (1)

NW10 7EW

GSK Investigational Site, London